Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis ; volume:50 ; number:1 ; day:1 ; month:3 ; year:2023 ; pages:1-9 ; date:12.2023
Egyptian rheumatology & rehabilitation ; 50, Heft 1 (1.3.2023), 1-9, 12.2023
- Urheber
-
Aboud, Fatma Mohammed
Galal, Salwa
Elwafa, Menna Allah Zakaria Abou
Farouk, ALshymaa Mohammed
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s43166-023-00174-0
- URN
-
urn:nbn:de:101:1-2023060221535047799918
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Aboud, Fatma Mohammed
- Galal, Salwa
- Elwafa, Menna Allah Zakaria Abou
- Farouk, ALshymaa Mohammed
- SpringerLink (Online service)
Ähnliche Objekte (12)
Hematological indices: potential markers of disease activity in ankylosing spondylitis patients treated with biological drugs
Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis
Andersson lesion in ankylosing spondylitis
Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice
Surgical treatment of ankylosing spondylitis deformity
Secukinumab: A Review in Ankylosing Spondylitis
Variants in RUNX3 contribute to susceptibility to psoriatic arthritis exhibiting further common ground with ankylosing spondylitis.
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Maternal Interleukin-17 and disease activity influence pregnancy outcomes in women with psoriatic arthritis and ankylosing spondylitis
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
ANKHvariants associated with ankylosing spondylitis: gender differences
Hematological indices: potential markers of disease activity in ankylosing spondylitis patients treated with biological drugs
Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis
Andersson lesion in ankylosing spondylitis
Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice
Surgical treatment of ankylosing spondylitis deformity
Secukinumab: A Review in Ankylosing Spondylitis
Variants in RUNX3 contribute to susceptibility to psoriatic arthritis exhibiting further common ground with ankylosing spondylitis.
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Maternal Interleukin-17 and disease activity influence pregnancy outcomes in women with psoriatic arthritis and ankylosing spondylitis
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
ANKHvariants associated with ankylosing spondylitis: gender differences
Hematological indices: potential markers of disease activity in ankylosing spondylitis patients treated with biological drugs
Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis
Andersson lesion in ankylosing spondylitis
Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice
Surgical treatment of ankylosing spondylitis deformity
Secukinumab: A Review in Ankylosing Spondylitis
Variants in RUNX3 contribute to susceptibility to psoriatic arthritis exhibiting further common ground with ankylosing spondylitis.
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Maternal Interleukin-17 and disease activity influence pregnancy outcomes in women with psoriatic arthritis and ankylosing spondylitis
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis